SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?


To: Oliver & Co who wrote (3436)12/27/1997 1:52:00 AM
From: billkirn  Read Replies (2) | Respond to of 6136
 
Just to keep this infront of us. "Lilly recently pulled their GART inhibitor off trials due to some very serious side effects."
Agouron's AG2043 is a GART inhibitor and one of the drugs entering PhaseII in 1998. AG3340 is their MMP which seems to be going well.
Next week I will ask IR if this affects their plans for AG2043 trials?
Bill